Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, announced the opening of its new global headquarters at 215 First Street in Cambridge’s Kendall Square. Sarepta executives, directors and employees celebrated the announcement at a ribbon-cutting ceremony with several federal, state, and local government officials from Massachusetts, leaders of the Massachusetts life sciences and biotechnology communities, and representatives from leading Duchenne muscular dystrophy (DMD) patient advocacy groups. The new headquarters includes approximately 45,000 square feet of office and laboratory space capable of supporting early stage drug discovery and development.
